KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Research & Development: 2011-2024

Historic Research & Development for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $804.5 million.

  • Sarepta Therapeutics' Research & Development rose 13.75% to $204.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.2 billion, marking a year-over-year increase of 59.61%. This contributed to the annual value of $804.5 million for FY2024, which is 8.30% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Research & Development of $804.5 million as of FY2024, which was down 8.30% from $877.4 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Research & Development registered a high of $877.4 million during FY2023, and its lowest value of $722.3 million during FY2020.
  • For the 3-year period, Sarepta Therapeutics' Research & Development averaged around $853.0 million, with its median value being $877.1 million (2022).
  • As far as peak fluctuations go, Sarepta Therapeutics' Research & Development grew by 28.78% in 2020, and later fell by 8.30% in 2024.
  • Sarepta Therapeutics' Research & Development (Yearly) stood at $722.3 million in 2020, then increased by 6.76% to $771.2 million in 2021, then climbed by 13.73% to $877.1 million in 2022, then grew by 0.03% to $877.4 million in 2023, then decreased by 8.30% to $804.5 million in 2024.